NCT03168308View on ClinicalTrials.gov

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Neuromuscular Blockade
Interventions
DRUG

Sugammadex

Sugammadex 2 mg/kg

DRUG

Neostigmine w/ Glycopyrrolate

Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg

Trial Locations (1)

75211

Parkland Health & Hospital System, Dallas

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT03168308 - Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients | Biotech Hunter | Biotech Hunter